60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ:SXTP
Want to see SXTP full AI Analyst Report?
SXTP Stock Chart & Stats
$0.50
-$0.08(-5.71%)
At close: 4:00 PM EST
$0.50
-$0.08(-5.71%)
Day’s Range― - ―
52-Week Range$1.29 - $14.68
Previous CloseN/A
Volume13.44M
Average Volume (3M)199.18K
Market Cap
$3.96M
Enterprise Value-$1.98M
Total Cash (Recent Filing)$3.34M
Total Debt (Recent Filing)$151.97K
Price to Earnings (P/E)―
Beta2.43
Next Earnings
Aug 19, 2026EPS Estimate
-0.74Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.15
Shares Outstanding2,659,288
10 Day Avg. Volume488,900
30 Day Avg. Volume199,179
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.39
Price to Sales (P/S)1.35
P/FCF Ratio-0.19
Enterprise Value/Market Cap-0.50
Enterprise Value/Revenue-1.98
Enterprise Value/Gross Profit-9.45
Enterprise Value/Ebitda0.26
Forecast
1Y Price Target
$4.20Price Target Upside740.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.16
Revenue Forecast (FY)$1.30M
Bulls Say, Bears Say
Bulls Say
Clinical Evidence And Indication ExpansionAnalyst highlights clinical trial data showing cures in patients with relapsing babesiosis who failed prior treatments, indicating potential to expand ARAKODA use into high‑need indications and broaden the addressable market.
Market Opportunity And Commercial InitiativesAnalyst emphasizes that the large infectious disease market and company efforts to raise awareness, conduct physician outreach, and collaborate with payers and pharmacies could increase treatment uptake and drive future growth.
Partnerships And DistributionAnalyst notes the GoodRx partnership lowers patient out-of-pocket costs and expands nationwide availability, which could accelerate ARAKODA revenue growth by making the product easier to access.
Bears Say
Commercial TractionAnalyst notes that modest ARAKODA sales highlight a need for improved market traction, and continued slow uptake could pressure revenue expectations and investor sentiment.
Liquidity And Financing RiskAnalyst warns that limited cash resources could constrain operations and create the need for additional financing, which may lead to dilution or slower progress on commercial programs.
60 Degrees Pharmaceuticals, Inc. News
SXTP FAQ
What was 60 Degrees Pharmaceuticals, Inc.’s price range in the past 12 months?
60 Degrees Pharmaceuticals, Inc. lowest stock price was $1.29 and its highest was $14.68 in the past 12 months.
What is 60 Degrees Pharmaceuticals, Inc.’s market cap?
60 Degrees Pharmaceuticals, Inc.’s market cap is $3.96M.
When is 60 Degrees Pharmaceuticals, Inc.’s upcoming earnings report date?
60 Degrees Pharmaceuticals, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 79 days.
How were 60 Degrees Pharmaceuticals, Inc.’s earnings last quarter?
Currently, no data Available
Is 60 Degrees Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts 60 Degrees Pharmaceuticals, Inc.’s price is currently Undervalued.
Does 60 Degrees Pharmaceuticals, Inc. pay dividends?
60 Degrees Pharmaceuticals, Inc. does not currently pay dividends.
What is 60 Degrees Pharmaceuticals, Inc.’s EPS estimate?
60 Degrees Pharmaceuticals, Inc.’s EPS estimate is -0.74.
How many shares outstanding does 60 Degrees Pharmaceuticals, Inc. have?
60 Degrees Pharmaceuticals, Inc. has 2,659,288 shares outstanding.
What happened to 60 Degrees Pharmaceuticals, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of 60 Degrees Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in SXTP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria preventative treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis. The company was founded in 2010 and is headquartered in Washington, District Of Columbia.
SXTP Stock 12 Month Forecast
Average Price Target
$4.20
▲(740.00% Upside)
Technical Analysis
Ownership Overview
3.01% Insiders
0.33% Mutual Funds
5.44% Other Institutional Investors
91.22% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---